You searched for "Tumour"

217 results found

Precision study with the Raypilot ® system now underway

Micropos Medical is a Swedish company developing technology for enhanced radiotherapy cancer treatment. Their Raypilot® System offers accuracy through real-time tumor tracking in prostate cancer radiation treatment. The 2024 Pace-B study showed that SBRT with five sessions is as effective...

The multidisciplinary team meeting: London calling!

The multidisciplinary team meeting, or MDT, is the foundation of cancer management in the UK. The MDT consists of a group of experts in different fields of medicine and surgery coming together at regular intervals to discuss the diagnosis and...

Cystitis Unmasked

Cystitis is often viewed as a heartsink diagnosis, and sometimes one of exclusion. The aetiology is multifactorial and misunderstood. Treatment has been based on dogma, and poor clinical and scientific evidence. The truth is, that despite the significant morbidity caused...

The adrenals

Case 1 A 45-year-old man undergoes a CT of his abdomen to stage a newly diagnosed bowel malignancy. What does the scan show? What findings on a CT scan suggest an adrenal lesion is benign? If the CT scan is...

Ureteric strictures

Case 1 What is this investigation? What are the findings of this investigation? What are the causes for this? What are the treatment options? Case 2 Image 1. Image 2. What do these X-Ray KUB films show? What are the...

Joaquín Albarrán (1860–1912), the gifted promise

In this series of articles, I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). Does the name Joaquín Albarrán mean anything to you? Maybe you remember using...

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...

Bladder cancer – an overshadowed ‘volcano’

Bladder cancer has often been overshadowed by the limelight of prostate cancer. However, of all the urological cancers, bladder cancer is the only one which has shown a slight decline in age-standardised five-year survival rates over the last couple of...

The PROMIS trial – time for multi-parametric MRI before a first prostate biopsy

Whilst the relatively random process of 12 core transrectal ultrasound guided (TRUS) prostate biopsy remains by far the most widely employed approach to prostate cancer diagnosis in the UK, its flaws as a standalone diagnostic strategy are increasingly apparent. TRUS-biopsy...

Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade

This is an interesting paper reporting on the use of neoadjuvant androgen blockage in patients with high-risk prostate cancer undergoing radical prostatectomy. Previous work in the literature has shown an improvement in the rate of organ-confined disease and decreased positive...

The natural history of prostate cancer on MRI

Multiparametric MRI features heavily on a number of active surveillance protocols. This study looked at 86 men on active surveillance who had an mpMRI prior to 2013 to assess how lesions changed over time. Two blinded radiologists examined all the...

Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy

Neutrophil-to-lymphocyte ratio has been shown to be a prognostic factor in a number of different cancers. This is one of the largest studies to date to evaluate its effect on overall survival in patients who have undergone radical prostatectomy (RP)...